The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1675
May 1, 2023
View Complete Issue         Table of Contents 2019 
Altuviiio – A Longer-Acting Factor VIII Product for Hemophilia A
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Altuviiio – A Longer-Acting Factor VIII Product for Hemophilia A
May 1, 2023 (Issue: 1675)
The FDA has approved Altuviiio (Sanofi), a von Willebrand Factor (VWF)-independent, recombinant factor VIII concentrate, for routine prophylaxis, on-demand treatment to control bleeding episodes, and perioperative management of bleeding in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Altuviiio – A Longer-Acting Factor VIII Product for Hemophilia A
Article code: 1675b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.